Locally Advanced HER2+ Breast Cancer

Opinion
Video

Panelists discuss how, locally advanced HER2-positive breast cancer is characterized by overexpression of HER2 proteins with regional spread beyond the primary tumor, involving either extensive lymph node involvement, chest wall, or skin, but without distant metastases. Treatment typically combines targeted HER2 therapy, chemotherapy, and local interventions.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
4 experts in this video
4 experts in this video
5 experts are featured in this series
Related Content
Applying Updated Findings From SABCS 2023 to HER2+ Breast Cancer Practice

Applying Updated Findings From SABCS 2023 to HER2+ Breast Cancer Practice

ONCOLOGY Staff
August 19th 2025
Article
1 expert in this video

Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025

Steven Finkelstein, MD, DABR, FACRO
August 19th 2025
Podcast
Targeted Therapy Options for HER2+ Breast Cancer

Targeted Therapy Options for HER2+ Breast Cancer

ONCOLOGY Staff
August 19th 2025
Article
1 expert in this video

CCR Scores and Beyond: Precision Strategies for Treatment Intensification in Prostate Cancer

Alvaro A. Martinez, MD
August 19th 2025
Podcast
Combining tucatinib with ado-trastuzumab emtansine does not appear to result in any new safety signals in the treatment of those with locally advanced or metastatic HER2-positive breast cancer.

Tucatinib/T-DM1 Yields ‘Encouraging’ PFS in Unresectable HER2+ Breast Cancer

Russ Conroy
August 19th 2025
Article
Findings from the phase 3 DESTINY-Breast04 trial supported the approval of fam-trastuzumab deruxtecan-nxki for HER2-low breast cancer in China.

Trastuzumab Deruxtecan Receives Chinese Approval in HER2-Low Breast Cancer

Hayley Virgil
August 19th 2025
Article